Price
No data yet.
Social Signal Score
Analyst Ratings
26 analystsRevenue
$360.52M+1468.43%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Matthew Klein
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 991
- Beta
- 0.55
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.80
Financials
Revenue
$360.52M+1468.4%Net Income
$83.50MEBITDA
$161.90MFree Cash Flow
$121.97MEPS (diluted)
$0.92Shares Outstanding (diluted)
92.02M+169.9%Operating Expenses
$179.78MCash & Debt
$2.23BRevenue by Segment (annual)
$1.83BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.73B | $682.64M | $8.58 |
| 2024 | $806.78M | $-363.30M | $-4.73 |
| 2023 | $937.82M | $-626.60M | $-8.37 |
| 2022 | $698.80M | $-559.02M | $-7.79 |
| 2021 | $538.59M | $-523.90M | $-7.43 |
| 2020 | $380.77M | $-438.16M | $-6.64 |
| 2019 | $306.98M | $-251.58M | $-4.27 |
| 2018 | $264.73M | $-128.08M | $-2.75 |
| 2017 | $194.39M | $-79.00M | $-2.02 |
| 2016 | $82.70M | $-142.11M | $-4.17 |
| 2015 | $36.77M | $-170.45M | $-5.07 |
| 2014 | $22.96M | $-93.75M | $-2.97 |
| 2013 | $31.33M | $-51.57M | $-4.02 |
| 2012 | $28.78M | $-26.24M | $-1.85 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $12.61
- Implied price
- $113.50
- Return from $63.46
- 12.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $56.43 — -11.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| -2.0% | -9.4% | -3.1% | 1.9% | 6.1% | 9.7% |
| 3.0% | -4.8% | 1.9% | 7.1% | 11.5% | 15.3% |
| 8.0% | -0.1% | 6.8% | 12.3% | 16.9% | 20.9% |
| 13.0% | 4.5% | 11.8% | 17.5% | 22.3% | 26.5% |
| 18.0% | 9.1% | 16.7% | 22.7% | 27.8% | 32.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
170+142.86%Social Signal Score
Mentions (4)
- News (RSS)seekingalpha·20d ago·Positive
PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·20d ago·Positive
PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·43d ago·Neutral
PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential
View source ↗ - Newsseekingalpha.com·54d ago·Positive
PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.29 per share
Typical surprise +93.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.92 vs $0.24beat
- Thu, May 7$-0.03 vs $-0.45beat
- Thu, Feb 19$-1.67 vs $-0.21miss
- Tue, Nov 4$0.20 vs $-1.19beat
- Thu, Aug 7$-0.83 vs $-1.07beat
- Tue, May 6$10.04 vs $-1.08beat
Estimates and results for PTCT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PTCT officers and directors.
- Bought
- —
- Sold
- $19.9m
0 trades
50 trades
- Steele Glenn Jr Md Phdsold
- Schmertzler Michaelsold
- Schmertzler Michaelsold
- Schmertzler Michaelsold
- Schmertzler Michaelsold
- Schmertzler Michaelsold
- Schmertzler Michaelsold
- Schmertzler Michaelsold
50 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PTCT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.